ArticlePloS one2020

Cost-Effectiveness of ramucirumab plus paclitaxel as a second-line therapy for advanced gastric or gastro-oesophageal cancer in China.

Sini Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.